Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

CymaBay Therapeutics, Inc. (CBAY)

9.59   0.45 (4.92%) 03-17 16:00
Open: 9.05 Pre. Close: 9.14
High: 10.05 Low: 9.05
Volume: 4,187,036 Market Cap: 908(M)

Technical analysis

as of: 2023-03-20 8:44:46 AM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 11.73     One year: 13.71
Support: Support1: 8.38    Support2: 7.34
Resistance: Resistance1: 10.05    Resistance2: 11.73
Pivot: 8.72
Moving Average: MA(5): 9.22     MA(20): 8.56
MA(100): 5.96     MA(250): 4.2
MACD: MACD(12,26): 0.4     Signal(9): 0.3
Stochastic oscillator: %K(14,3): 80.3     %D(3): 81.7
RSI: RSI(14): 66.2
52-week: High: 10.05  Low: 1.66
Average Vol(K): 3-Month: 1,629 (K)  10-Days: 2,010 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ CBAY ] has closed below upper band by 7.8%. Bollinger Bands are 49.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 10.06 - 10.1 10.1 - 10.13
Low: 8.96 - 9 9 - 9.04
Close: 9.52 - 9.59 9.59 - 9.65

Company Description

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

Headline News

Mon, 20 Mar 2023
Analysts Offer Predictions for CymaBay Therapeutics, Inc.'s Q1 2023 ... - MarketBeat

Sat, 18 Mar 2023
HC Wainwright Boosts CymaBay Therapeutics (NASDAQ:CBAY ... - MarketBeat

Thu, 16 Mar 2023
CymaBay Reports Fourth Quarter and Year Ended December 31, 2022 Financial Results and Provides Corporate Update - Yahoo Finance

Thu, 16 Mar 2023
After-Hours Earnings Report for March 16, 2023 : FDX, MNTK ... - Nasdaq

Tue, 14 Mar 2023
Cymabay Therapeutics Inc : A loss of 30 cents per share ... - Kalkine Media

Tue, 14 Mar 2023
Cubist Systematic Strategies LLC increases its stake in CymaBay ... - Best Stocks

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 95 (M)
Shares Float 0 (M)
% Held by Insiders 0.3 (%)
% Held by Institutions 76.5 (%)
Shares Short 4,940 (K)
Shares Short P.Month 4,430 (K)

Stock Financials

EPS -1.35
EPS Est Next Qtl -0.16
EPS Est This Year -0.82
EPS Est Next Year -0.75
Book Value (p.s.) 0.7
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) 0
Return on Equity (ttm) 0
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)

Stock Valuations

PE Ratio -7.16
PEG Ratio 0
Price to Book value 13.5
Price to Sales 0
Price to Cash Flow 0

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.